GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Torii Pharmaceutical Co Ltd (TSE:4551) » Definitions » 14-Day RSI

Torii Pharmaceutical Co (TSE:4551) 14-Day RSI : 48.88 (As of May. 15, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Torii Pharmaceutical Co 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-15), Torii Pharmaceutical Co's 14-Day RSI is 48.88.

The industry rank for Torii Pharmaceutical Co's 14-Day RSI or its related term are showing as below:

TSE:4551's 14-Day RSI is ranked better than
56.23% of 1140 companies
in the Drug Manufacturers industry
Industry Median: 50.705 vs TSE:4551: 48.88

Competitive Comparison of Torii Pharmaceutical Co's 14-Day RSI

For the Drug Manufacturers - Specialty & Generic subindustry, Torii Pharmaceutical Co's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Torii Pharmaceutical Co's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Torii Pharmaceutical Co's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Torii Pharmaceutical Co's 14-Day RSI falls into.



Torii Pharmaceutical Co  (TSE:4551) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Torii Pharmaceutical Co  (TSE:4551) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Torii Pharmaceutical Co 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Torii Pharmaceutical Co's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Torii Pharmaceutical Co (TSE:4551) Business Description

Traded in Other Exchanges
N/A
Address
Torii Nihonbashi Buildingg, 4-1, Nihonbashi-Honcho, 3-chome, Chuo-ku, Tokyo, JPN, 103-8439
Torii Pharmaceutical Co Ltd is a major drug manufacturing company. The company utilizes strategic partnerships with other pharmaceutical companies in order to combine research and marketing functions. Torii's key therapeutic areas include renal diseases, hemodialysis, HIV, skin diseases, and allergens. The vast majority of the company's net mainstay product sales are derived from the renal diseases and hemodialysis operations, followed by HIV. Torii's places its strategic focus on prompt market penetration and expansion of new products as well as maximizing values of mainstay products in each priority area.

Torii Pharmaceutical Co (TSE:4551) Headlines

No Headlines